A PILOT STUDY OF A STEROID SULPHATASE INHIBITOR (BN83495) IN PATIENTS WITH RASH DUE TO TREATMENT WITH AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)

被引:0
|
作者
Mileshkin, Linda [1 ]
Mccormack, Chris [1 ]
Michael, Michael [1 ]
Solomon, Ben [1 ]
Urban, Damien [1 ]
Link, Emma [1 ]
Cowan, Linda [1 ]
Zalcberg, John [1 ]
机构
[1] Peter MacCallum Canc Ctr, Div Canc Med, East Melbourne, Vic, Australia
关键词
rash; EGFR; NSCLC; supportive care;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P2.24-041
引用
收藏
页码:S1020 / S1020
页数:1
相关论文
共 50 条
  • [21] Fitness of RECIST 1.1 for non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitor (TKI)
    Sun, Jong-Mu
    Park, Min Jae
    Yi, Jun Ho
    Kong, Jeehyun
    Kim, Jung-A
    Lee, Soohyeon
    Yun, Lin A.
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S716 - S716
  • [22] SERUM PROTEIN LEVELS MAY BE USEFUL IN SELECTING TREATMENT WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR TKI) VERSUS CHEMOTHERAPY IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Fidler, Mary J.
    Karmali, Reem
    Batus, Marta
    Mahon, Brett
    Rouhi, Omid
    Shersher, David D.
    Fhied, Cristina
    Walters, Kelly
    Bonomi, Philip
    Borgia, Jeffrey A.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1113 - S1114
  • [23] Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer
    Noda, Shoko
    Kanda, Shintaro
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (05) : 547 - 556
  • [24] Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation
    Yan, Xiangtao
    Wang, Huijuan
    Li, Peng
    Zhang, Guowei
    Zhang, Mina
    Yang, Jinpo
    Zhang, Xiaojuan
    Zheng, Xuanxuan
    Ma, Zhiyong
    LUNG CANCER, 2019, 128 : 6 - 12
  • [25] Epidermal growth factor receptor tyrosine kinase inhibitor in treatment of brain metastasis from non-small cell lung cancer
    Zhang, Lan-jun
    Cai, Ling
    Zhu, Jian-fei
    Rong, Tie-hua
    Wu, Shao-xiong
    Chen, Zhong-pin
    Liu, Meng-zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] ACTIVATION OF CYTOMEGALOVIRUS IN A PATIENT ON EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR TREATMENT IN NON-SMALL CELL LUNG CANCER
    Dawes, Sean M.
    Plichta, Christine
    Gaddipati, Himaja
    Hamade, Sam
    Biedny, Adam
    de Villate, Oscar F. Parodi Ortiz
    CHEST, 2023, 164 (04) : 972A - 973A
  • [27] Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR- mutated advanced non-small cell lung cancer (NSCLC)
    Leighl, N.
    Karaseva, N.
    Nakagawa, K.
    Cho, B. -C.
    Gray, J. E.
    Hovey, T.
    Walding, A.
    Ryden, A.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S81 - S82
  • [28] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [29] Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
    Lee, Sanghun
    Joo, Jeonghyun
    Kwak, Minah
    Sohn, Kicheul
    Chon, Songha
    ONCOTARGETS AND THERAPY, 2018, 11 : 3943 - 3947
  • [30] A COMPARATIVE STUDY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN TREATMENT OF PATIENTS WITH BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER
    Zhang, L.
    Cai, L.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 421 - 421